UK GPs to test for asthma using Pharmaxis’ Aridol

By Renate Krelle
Thursday, 12 August, 2004

Having recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.

This will be the first in-field use of Aridol by GPs, and will allow comparisons between Aridol and existing diagnosis techniques used for asthma and chronic obstructive pulmonary disease. Some 16 per cent of people now diagnosed with asthma do not have the disease. The study will follow patients for 12 months and is expected to complete in 2006.

Pharmaxis, meanwhile, is analysing its Phase III data, a process expected to be completed by September. A positive outcome would allow the company to apply to Australian and European pharmaceutical regulatory agencies later this year for permission to begin marketing the test in 2005.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd